T(6;11) Renal cell carcinoma (RCC)

Expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases

Nathaniel E. Smith, Peter B. Illei, Mohamed Allaf, Nilda Gonzalez, Kerry Morris, Jessica Hicks, Angelo Demarzo, Victor E. Reuter, Mahul Amin, Jonathan I. Epstein, George J. Netto, Pedram Argani

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Renal cell carcinomas (RCCs) harboring the t(6;11)(p21;q12) translocation were first described in 2001 and recently recognized by the 2013 International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. Although these RCCs are known to label for melanocytic markers HMB45 and Melan A and the cysteine protease cathepsin K by immunohistochemistry (IHC), a comprehensive IHC profile has not been reported. We report 10 new t(6;11) RCCs, all confirmed by break-apart TFEB fluorescence in situ hybridization. A tissue microarray containing 6 of these cases and 7 other previously reported t(6;11) RCCs was constructed and immunolabeled for 21 different antigens. Additional whole sections of t(6;11) RCC were labeled with selected IHC markers. t(6;11) RCC labeled diffusely and consistently for cathepsin K and Melan A (13 of 13 cases) and almost always at least focally for HMB45 (12 of 13 cases). They labeled frequently for PAX8 (14 of 23 cases), CD117 (10 of 14 cases), and vimentin (9 of 13 cases). A majority of cases labeled at least focally for cytokeratin Cam5.2 (8 of 13 cases) and CD10 and RCC marker antigen (10 of 14 cases each). In contrast to a prior study's findings, only a minority of cases labeled for Ksp-cadherin (3 of 19 cases). The median H score (product of intensity score and percentage labeling) for phosphorylated S6, a marker of mTOR pathway activation, was 101, which is high relative to most other RCC subtypes. In summary, IHC labeling for PAX8, Cam5.2, CD10, and RCC marker antigen supports classification of the t(6;11) RCC as carcinomas despite frequent negativity for broad-spectrum cytokeratins and EMA. Labeling for PAX8 distinguishes the t(6;11) RCC from epithelioid angiomyolipoma, which otherwise shares a similar immunoprofile. CD117 labeling is more frequent in the t(6;11) RCC compared with the related Xp11 translocation RCC. Increased pS6 expression suggests a possible molecular target for the uncommon t(6;11) RCCs that metastasize.

Original languageEnglish (US)
Pages (from-to)604-614
Number of pages11
JournalAmerican Journal of Surgical Pathology
Volume38
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Renal Cell Carcinoma
Immunohistochemistry
MART-1 Antigen
Cathepsin K
Differentiation Antigens
Keratin-8
Angiomyolipoma
S 6
Endopeptidase K
Cysteine Proteases
Vimentin
Cadherins
Keratins
Fluorescence In Situ Hybridization
Pathology

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

T(6;11) Renal cell carcinoma (RCC) : Expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. / Smith, Nathaniel E.; Illei, Peter B.; Allaf, Mohamed; Gonzalez, Nilda; Morris, Kerry; Hicks, Jessica; Demarzo, Angelo; Reuter, Victor E.; Amin, Mahul; Epstein, Jonathan I.; Netto, George J.; Argani, Pedram.

In: American Journal of Surgical Pathology, Vol. 38, No. 5, 01.01.2014, p. 604-614.

Research output: Contribution to journalArticle

Smith, NE, Illei, PB, Allaf, M, Gonzalez, N, Morris, K, Hicks, J, Demarzo, A, Reuter, VE, Amin, M, Epstein, JI, Netto, GJ & Argani, P 2014, 'T(6;11) Renal cell carcinoma (RCC): Expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases', American Journal of Surgical Pathology, vol. 38, no. 5, pp. 604-614. https://doi.org/10.1097/PAS.0000000000000203
Smith, Nathaniel E. ; Illei, Peter B. ; Allaf, Mohamed ; Gonzalez, Nilda ; Morris, Kerry ; Hicks, Jessica ; Demarzo, Angelo ; Reuter, Victor E. ; Amin, Mahul ; Epstein, Jonathan I. ; Netto, George J. ; Argani, Pedram. / T(6;11) Renal cell carcinoma (RCC) : Expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. In: American Journal of Surgical Pathology. 2014 ; Vol. 38, No. 5. pp. 604-614.
@article{f6f99ff4478c4bb5b401b085dd2bec00,
title = "T(6;11) Renal cell carcinoma (RCC): Expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases",
abstract = "Renal cell carcinomas (RCCs) harboring the t(6;11)(p21;q12) translocation were first described in 2001 and recently recognized by the 2013 International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. Although these RCCs are known to label for melanocytic markers HMB45 and Melan A and the cysteine protease cathepsin K by immunohistochemistry (IHC), a comprehensive IHC profile has not been reported. We report 10 new t(6;11) RCCs, all confirmed by break-apart TFEB fluorescence in situ hybridization. A tissue microarray containing 6 of these cases and 7 other previously reported t(6;11) RCCs was constructed and immunolabeled for 21 different antigens. Additional whole sections of t(6;11) RCC were labeled with selected IHC markers. t(6;11) RCC labeled diffusely and consistently for cathepsin K and Melan A (13 of 13 cases) and almost always at least focally for HMB45 (12 of 13 cases). They labeled frequently for PAX8 (14 of 23 cases), CD117 (10 of 14 cases), and vimentin (9 of 13 cases). A majority of cases labeled at least focally for cytokeratin Cam5.2 (8 of 13 cases) and CD10 and RCC marker antigen (10 of 14 cases each). In contrast to a prior study's findings, only a minority of cases labeled for Ksp-cadherin (3 of 19 cases). The median H score (product of intensity score and percentage labeling) for phosphorylated S6, a marker of mTOR pathway activation, was 101, which is high relative to most other RCC subtypes. In summary, IHC labeling for PAX8, Cam5.2, CD10, and RCC marker antigen supports classification of the t(6;11) RCC as carcinomas despite frequent negativity for broad-spectrum cytokeratins and EMA. Labeling for PAX8 distinguishes the t(6;11) RCC from epithelioid angiomyolipoma, which otherwise shares a similar immunoprofile. CD117 labeling is more frequent in the t(6;11) RCC compared with the related Xp11 translocation RCC. Increased pS6 expression suggests a possible molecular target for the uncommon t(6;11) RCCs that metastasize.",
author = "Smith, {Nathaniel E.} and Illei, {Peter B.} and Mohamed Allaf and Nilda Gonzalez and Kerry Morris and Jessica Hicks and Angelo Demarzo and Reuter, {Victor E.} and Mahul Amin and Epstein, {Jonathan I.} and Netto, {George J.} and Pedram Argani",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/PAS.0000000000000203",
language = "English (US)",
volume = "38",
pages = "604--614",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - T(6;11) Renal cell carcinoma (RCC)

T2 - Expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases

AU - Smith, Nathaniel E.

AU - Illei, Peter B.

AU - Allaf, Mohamed

AU - Gonzalez, Nilda

AU - Morris, Kerry

AU - Hicks, Jessica

AU - Demarzo, Angelo

AU - Reuter, Victor E.

AU - Amin, Mahul

AU - Epstein, Jonathan I.

AU - Netto, George J.

AU - Argani, Pedram

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Renal cell carcinomas (RCCs) harboring the t(6;11)(p21;q12) translocation were first described in 2001 and recently recognized by the 2013 International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. Although these RCCs are known to label for melanocytic markers HMB45 and Melan A and the cysteine protease cathepsin K by immunohistochemistry (IHC), a comprehensive IHC profile has not been reported. We report 10 new t(6;11) RCCs, all confirmed by break-apart TFEB fluorescence in situ hybridization. A tissue microarray containing 6 of these cases and 7 other previously reported t(6;11) RCCs was constructed and immunolabeled for 21 different antigens. Additional whole sections of t(6;11) RCC were labeled with selected IHC markers. t(6;11) RCC labeled diffusely and consistently for cathepsin K and Melan A (13 of 13 cases) and almost always at least focally for HMB45 (12 of 13 cases). They labeled frequently for PAX8 (14 of 23 cases), CD117 (10 of 14 cases), and vimentin (9 of 13 cases). A majority of cases labeled at least focally for cytokeratin Cam5.2 (8 of 13 cases) and CD10 and RCC marker antigen (10 of 14 cases each). In contrast to a prior study's findings, only a minority of cases labeled for Ksp-cadherin (3 of 19 cases). The median H score (product of intensity score and percentage labeling) for phosphorylated S6, a marker of mTOR pathway activation, was 101, which is high relative to most other RCC subtypes. In summary, IHC labeling for PAX8, Cam5.2, CD10, and RCC marker antigen supports classification of the t(6;11) RCC as carcinomas despite frequent negativity for broad-spectrum cytokeratins and EMA. Labeling for PAX8 distinguishes the t(6;11) RCC from epithelioid angiomyolipoma, which otherwise shares a similar immunoprofile. CD117 labeling is more frequent in the t(6;11) RCC compared with the related Xp11 translocation RCC. Increased pS6 expression suggests a possible molecular target for the uncommon t(6;11) RCCs that metastasize.

AB - Renal cell carcinomas (RCCs) harboring the t(6;11)(p21;q12) translocation were first described in 2001 and recently recognized by the 2013 International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. Although these RCCs are known to label for melanocytic markers HMB45 and Melan A and the cysteine protease cathepsin K by immunohistochemistry (IHC), a comprehensive IHC profile has not been reported. We report 10 new t(6;11) RCCs, all confirmed by break-apart TFEB fluorescence in situ hybridization. A tissue microarray containing 6 of these cases and 7 other previously reported t(6;11) RCCs was constructed and immunolabeled for 21 different antigens. Additional whole sections of t(6;11) RCC were labeled with selected IHC markers. t(6;11) RCC labeled diffusely and consistently for cathepsin K and Melan A (13 of 13 cases) and almost always at least focally for HMB45 (12 of 13 cases). They labeled frequently for PAX8 (14 of 23 cases), CD117 (10 of 14 cases), and vimentin (9 of 13 cases). A majority of cases labeled at least focally for cytokeratin Cam5.2 (8 of 13 cases) and CD10 and RCC marker antigen (10 of 14 cases each). In contrast to a prior study's findings, only a minority of cases labeled for Ksp-cadherin (3 of 19 cases). The median H score (product of intensity score and percentage labeling) for phosphorylated S6, a marker of mTOR pathway activation, was 101, which is high relative to most other RCC subtypes. In summary, IHC labeling for PAX8, Cam5.2, CD10, and RCC marker antigen supports classification of the t(6;11) RCC as carcinomas despite frequent negativity for broad-spectrum cytokeratins and EMA. Labeling for PAX8 distinguishes the t(6;11) RCC from epithelioid angiomyolipoma, which otherwise shares a similar immunoprofile. CD117 labeling is more frequent in the t(6;11) RCC compared with the related Xp11 translocation RCC. Increased pS6 expression suggests a possible molecular target for the uncommon t(6;11) RCCs that metastasize.

UR - http://www.scopus.com/inward/record.url?scp=84899491174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899491174&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000203

DO - 10.1097/PAS.0000000000000203

M3 - Article

VL - 38

SP - 604

EP - 614

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 5

ER -